FindTrial
Sign In

Screening of markers related to the efficacy of metafenib tablets and MB07133 for injection in the treatment of middle-advanced primary liver cancer and its mechanism of action based on the PDX model and the role of NK cells in different treatment stages of liver cancer patients

Individualized therapy study of metafenib and MB07133 in the treatment of advanced primary liver cancer based on mini PDX drug susceptibility detection and small sample sequencing technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055227
Enrollment
Unknown
Registered
2022-01-03
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

case series:Nil

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent form: (1) The subjects voluntarily signed a written informed consent; (2) The subject can communicate well with the investigator and complete the trial in accordance with the protocol. 2. Target population: According to the 2018 CSCO Guidelines for the Treatment of Primary Liver Cancer, patients with advanced primary liver cancer diagnosed by pathological diagnosis (pathological histology and/or cytology) or clinical diagnosis (dynamic-enhanced MRI or dynamic-enhanced CT scan) .

Exclusion criteria

Exclusion criteria: 1. Those who cannot cooperate with return visits and questionnaires; 2. Those who are judged by the investigator to be unsuitable to continue participating in this trial.

Design outcomes

Primary

MeasureTime frame
DNAseq;—

Countries

China

Contacts

Public ContactDing Yanhua

The First Hospital of Jilin University

dingyanh@jlu.edu.cn+86 18186879768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026